The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...
Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...
StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a research note released on Friday morning. The firm issued a hold rating on the stock. Trinity Biotech Price ...
Hosted on MSN20d
Trinity Biotech’s CGM System Shows Breakthrough ImprovementsTrinity Biotech ( (TRIB)) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous glucose monitoring (CGM) system, following its latest pre ...
DUBLIN, Ireland - Trinity Biotech plc (NASDAQ:TRIB), a leading provider of diagnostic solutions for the healthcare industry, today announced the continuation of U.S. government funding for its HIV ...
Shares of Trinity Biotech (NASDAQ:TRIB) traded sharply higher on Tuesday after the Irish MedTech reported encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose ...
DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...
Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based diagnostic company with a market capitalization of $23.7 million and current trading price of $1.32, is evaluating the potential effects of a ...
Trinity Biotech PLC (TRIB) reports a 3% revenue increase and outlines strategic initiatives for future growth and profitability. Trinity Biotech PLC (TRIB) reports a 14% revenue increase with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results